KOD

NASDAQ 已收盘

Kodiak Sciences

97.90 USD
▲+0.09+0.09%
盘后 98.00 +0.10%
2026-11-19
市值
$6.34B
市盈率
—
EPS
-4.08
股息率
—
52 周区间
19.04 – 112.79
成交量
521.86K
Beta
1.98
目标价
130.17
52W 低 19.0452W 高 112.79
价格走势

公司简介

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...

关联新闻